Bazoukis George, Tse Gary, Letsas Konstantinos P, Thomopoulos Costas, Naka Katerina K, Korantzopoulos Panagiotis, Bazoukis Xenophon, Michelongona Paschalia, Papadatos Stamatis S, Vlachos Konstantinos, Liu Tong, Efremidis Michael, Baranchuk Adrian, Stavrakis Stavros, Tsioufis Costas
Department of Cardiology Catheterization Laboratory Evangelismos General Hospital of Athens Athens Greece.
Department of Medicine and Therapeutics Faculty of Medicine Chinese University of Hong Kong Hong Kong China.
J Arrhythm. 2018 Jan 12;34(2):124-128. doi: 10.1002/joa3.12031. eCollection 2018 Apr.
Ranolazine is a new medication for the treatment of refractory angina. However, except its anti-anginal properties, it has been found to act as an anti-arrhythmic. The aim of our systematic review is to present the existing data about the impact of ranolazine in ventricular arrhythmias. We searched MEDLINE and Cochrane databases as well clinicaltrials.gov until September 1, 2017 to find all studies (clinical trials, observational studies, case reports/series) reported data about the impact of ranolazine in ventricular arrhythmias. Our search revealed 14 studies (3 clinical trials, 2 observational studies, 8 case reports, 1 case series). These data reported a beneficial impact of ranolazine in ventricular tachycardia/fibrillation, premature ventricular beats, and ICD interventions in different clinical settings. The existing data highlight the anti-arrhythmic properties of ranolazine in ventricular arrhythmias.
雷诺嗪是一种用于治疗顽固性心绞痛的新药。然而，除了其抗心绞痛特性外，还发现它具有抗心律失常作用。我们系统评价的目的是呈现关于雷诺嗪对室性心律失常影响的现有数据。我们检索了MEDLINE和Cochrane数据库以及clinicaltrials.gov，直至2017年9月1日，以查找所有报告了雷诺嗪对室性心律失常影响数据的研究（临床试验、观察性研究、病例报告/系列）。我们的检索发现了14项研究（3项临床试验、2项观察性研究、8例病例报告、1个病例系列）。这些数据报告了雷诺嗪在不同临床环境中对室性心动过速/颤动、室性早搏和植入式心律转复除颤器干预的有益影响。现有数据突出了雷诺嗪在室性心律失常中的抗心律失常特性。
